Phase II study of eribulin mesylate for treatment of CNS metastases (mets) in metastatic breast cancer (mBC).

Ariel Ann Nelson,Shivaprasad Manjappa,Yuvraj Choudhary,Cheryl L. Thompson,Jeanine Agler,Bethany Lawrence,Manmeet S. Ahluwalia,Paula Silverman

Phase II study of eribulin mesylate for treatment of CNS metastases (mets) in metastatic breast cancer (mBC).

2019

Ariel Ann Nelson
Shivaprasad Manjappa
Yuvraj Choudhary
Cheryl L. Thompson
Jeanine Agler
Bethany Lawrence
Manmeet S. Ahluwalia
Paula Silverman

e12571Background: There is no approved drug therapy for CNS mets from mBC. Eribulin mesylate (eribulin) is a microtubule inhibitor approved for treatment of mBC patients (pts) who have received at ...

Keywords:

Eribulin Mesylate
Phases of clinical research
Oncology
Pathology
Internal medicine
Metastatic breast cancer
Medicine
Approved drug
Eribulin
Microtubule Inhibitor

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations